- Home
- NVA vs MDXH Comparison
NVA vs MDXH Comparison
Compare NVA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVA
- MDXH
- Stock Information
- Founded
- NVA 1987
- MDXH 2003
- Country
- NVA Australia
- MDXH Belgium
- Employees
- NVA N/A
- MDXH N/A
- Industry
- NVA
- MDXH
- Sector
- NVA
- MDXH
- Exchange
- NVA NYSE
- MDXH Nasdaq
- Market Cap
- NVA 69.7M
- MDXH 73.3M
- IPO Year
- NVA N/A
- MDXH 2021
- Fundamental
- Price
- NVA $12.87
- MDXH $1.76
- Analyst Decision
- NVA
- MDXH Buy
- Analyst Count
- NVA 0
- MDXH 1
- Target Price
- NVA N/A
- MDXH $6.00
- AVG Volume (30 Days)
- NVA 18.8K
- MDXH 55.7K
- Earning Date
- NVA 01-01-0001
- MDXH 05-05-2025
- Dividend Yield
- NVA N/A
- MDXH N/A
- EPS Growth
- NVA N/A
- MDXH N/A
- EPS
- NVA N/A
- MDXH N/A
- Revenue
- NVA N/A
- MDXH $90,049,000.00
- Revenue This Year
- NVA N/A
- MDXH $23.38
- Revenue Next Year
- NVA N/A
- MDXH $16.84
- P/E Ratio
- NVA N/A
- MDXH N/A
- Revenue Growth
- NVA N/A
- MDXH 28.29
- 52 Week Low
- NVA $4.35
- MDXH $1.35
- 52 Week High
- NVA $19.00
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- NVA N/A
- MDXH 66.56
- Support Level
- NVA N/A
- MDXH $1.51
- Resistance Level
- NVA N/A
- MDXH $1.64
- Average True Range (ATR)
- NVA 0.00
- MDXH 0.08
- MACD
- NVA 0.00
- MDXH 0.04
- Stochastic Oscillator
- NVA 0.00
- MDXH 93.02
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.